Literature DB >> 10219330

New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.

G M Vujanić1, D Harms, B Sandstedt, A Weirich, J de Kraker, J F Delemarre.   

Abstract

BACKGROUND: Unlike the original definitions of focal (FA) and diffuse anaplasia (DA) in Wilms tumor (WT), recently redefined FA and DA proved to be of prognostic significance. The aim of the study was to analyze WT from the SIOP file, the majority of which were treated with preoperative chemotherapy, in order to investigate whether chemotherapy influenced the presence of anaplasia, whether the new definitions were applicable to these tumors, and whether they were of prognostic significance. PROCEDURE: The unilateral anaplastic WT of children up to 16 years of age from the SIOP 6 and 9 nephroblastoma trials and studies were first classified according to the original definitions and analyzed. Then they were reclassified and analyzed according to the new definitions.
RESULTS: Anaplasia was diagnosed in 86 (5.5%) of 1,554 unilateral WT. The age at diagnosis ranged from 9 to 175 months (median, 63) and more than half of children were over 5 years of age. From 15% to 85% of the tumor mass showed chemotherapy-induced changes. Blastemal anaplasia was seen in 74, stromal in 23, and epithelial in 22 cases. According to the original definitions, FA was diagnosed in 55 (64%) and DA in 31 (36%) cases. In total, 48% children were alive and well, including 53% with FA and 39% with DA (P = 0.23). When reclassified, 39 old FA cases were moved to the new DA group, resulting in 70 (81%) DA and 16 (19%) FA cases. The female-to-male ratio for FA changed from 1.9:1 to 1:1 while remained unchanged for DA. The percentage of FA stage I cases increased from 31% to 44%, while it decreased from 25% to 6% for stage III. For other stages it remained virtually unchanged. The overall 4-year actual survival was 75% for FA and 41% for DA (P = 0.03).
CONCLUSIONS: Preoperative chemotherapy did not obliterate or produce anaplasia. The new definitions were applicable to pretreated cases and they were of prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219330     DOI: 10.1002/(sici)1096-911x(199905)32:5<317::aid-mpo1>3.0.co;2-f

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  8 in total

Review 1.  Wilms tumor: what's new?

Authors:  Tomás Acha García; Carlota Calvo Escribano; José Alfaro Gutiérrez; Paloma Galarón García; Mercedes Guibelalde del Castillo
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

2.  Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.

Authors:  Najat C Daw; Yueh-Yun Chi; Yeonil Kim; Elizabeth A Mullen; John A Kalapurakal; Jing Tian; Geetika Khanna; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Anne B Warwick; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  Eur J Cancer       Date:  2019-07-17       Impact factor: 9.162

3.  Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.

Authors:  Najat C Daw; Yueh-Yun Chi; John A Kalapurakal; Yeonil Kim; Fredric A Hoffer; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Elizabeth A Mullen; Anne B Warwick; Paul E Grundy; Arnold C Paulino; Eric Gratias; Deborah Ward; James R Anderson; Geetika Khanna; Brett Tornwall; Conrad V Fernandez; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2020-03-05       Impact factor: 44.544

4.  Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.

Authors:  Takaharu Oue; Tsugumichi Koshinaga; Tetsuya Takimoto; Hajime Okita; Yukichi Tanaka; Miwako Nozaki; Masayuki Haruta; Yasuhiko Kaneko; Masahiro Fukuzawa
Journal:  Pediatr Surg Int       Date:  2016-07-29       Impact factor: 1.827

Review 5.  The current status of treatment of Wilms' tumor as per the SIOP trials.

Authors:  Jan Godzinski
Journal:  J Indian Assoc Pediatr Surg       Date:  2015-01

6.  TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.

Authors:  Jenny Wegert; Christian Vokuhl; Barbara Ziegler; Karen Ernestus; Ivo Leuschner; Rhoikos Furtwängler; Norbert Graf; Manfred Gessler
Journal:  J Pathol Clin Res       Date:  2017-08-14

Review 7.  Recent progress in the biology and treatment of Wilms' tumor.

Authors:  M L Ritchey
Journal:  Curr Urol Rep       Date:  2001-04       Impact factor: 2.862

8.  Immunohistochemical analysis of cyclin A expression in Wilms tumor.

Authors:  Sanja Radojević-Škodrić; Dimitrije Brašanac; Slaviša M Đuričić; Sofija Glumac; Zlatibor Lončar; Ivan Pavlović; Ana Todorović; Gorana Nikolić; Ivana Baralić; Snežana Pejić
Journal:  PeerJ       Date:  2019-01-11       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.